Answers are grounded in this paper and cite their sources.
Observational analysis finds higher recall rates for invasive chronic pain devices, suggesting regulatory evolution.
Despite shorter regulatory review, invasive chronic pain devices demonstrated substantially higher recall rates. The shift toward globally sourced noninvasive technologies reflects evolving regulatory-technological considerations.
No takes yet. Share an insight, caveat, or question.
Almarie et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: